With GLP-1 drugs gaining widespread popularity, the obesity drug development landscape is shifting toward next-generation therapeutics such as amylin analogues, multi-target agonists, and gene therapies. These complex mechanisms demand preclinical models with higher predictive accuracy to reduce the high attrition rate seen in clinical trials. Traditional diet-induced obesity (DIO) models, which focus mainly on body weight and food intake, often overlook critical pharmacodynamic dimensions like body composition, energy metabolism, insulin sensitivity, and target organ histopathology. This gap contributes to compounds failing in clinical trials despite promising preclinical results.
To address these limitations, Protheragen Obesity has established a tiered, customizable obesity models technical system. The system includes in vitro cell models for high-throughput screening, gene-edited models using CRISPR/Cas9 technology to precisely recapitulate human obesity-associated mutations (e.g., LEP, LEPR, MC4R), diet-induced models for obesity with comorbidities, and chemically or surgically induced models for specific mechanistic questions. Each model is equipped with comprehensive metabolic phenotyping covering DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance testing, and histopathological examination.
Protheragen Obesity operates under a GLP-compliant quality management system, with DIO studies achieving a model induction success rate exceeding 90%. All study reports meet FDA and NMPA requirements for IND-enabling pharmacology submissions. The company offers flexible collaboration models including full-service outsourcing, modular services, and co-development partnerships. Every engagement begins with a consultation phase where the technical team customizes the optimal model strategy based on the client's molecular modality and mechanism of action.
With extensive experience in metabolic disease research, Protheragen Obesity has supported dozens of biopharmaceutical companies in completing obesity drug development programs from target validation to IND submission. For more information, visit Protheragen Obesity.
